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Dystrophin is the recently discovered efective gene product in Duchenne and Becker muscular dystrophy (DMD and 
BMD). Dystrophin transcripts have been amplified and identified in diagnostic needle muscle biopsy samples using the 
polymerase chain reaction (PCR) procedure. Using S- and 3’-primers, dystrophin transcripts can be detected in both 
DMD and BMD muscle biopsies, on either side of defined deletions within the dystrophin gene. 
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1. INTRODUCTION 
Duchenne and Becker muscular dystrophy 
(DMD and BMD) are two allelic X-linked 
disorders which arise from mutation in the same 
gene [ 11. The gene has recently been identified and 
shown to span 2000 kilobases [2] comprising ap- 
prox. 0.05% of the human genome. The cor- 
responding human cDNA sequence has been 
isolated [3] and antibodies have been raised against 
a fusion protein constructed from a fragment of 
cDNA toward the 5 ’ -end of the molecule. This has 
led to the identification of a protein, dystrophin, 
which, although present in normal muscle, is ab- 
sent in skeletal muscle from boys with DMD [4,5]. 
Abnormal abundance or abnormal molecular mass 
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forms of dystrophin are found in patients with the 
milder BMD phenotype [5,6]. 
Approx. one-third of all cases of DMD (which 
affects 1 in 3500 newborn males) are due to a new 
mutation in the’ gene. In skeletal muscle, 
dystrophin is encoded by a large 14 kb RNA 
transcript processed from more than 65 exons; as 
a result, less than 1% of the total gene is tran- 
scribed and the large amount of splicing that takes 
place during transcription probably contributes to 
the high levels of mutation which are observed [7]. 
The large dystrophin transcript is rapidly degraded 
[8] and this degradation, coupled with its low 
abundance (O.OOl-0.01% total muscle RNA) 
makes the transcript very difficult to detect on 
Northern blots, using diagnostic muscle biopsy 
samples. Expression in the 5 ‘-end of the gene has 
been observed in DMD muscle however, par- 
ticularly in regenerating muscle fibres, using the 
greater sensitivity of in situ RNA hybridization [8]. 
Using the polymerase chain reaction (PCR), 
dystrophin mRNA can be detected in many tissues 
[9,10]. Unlike Northern blot analysis, which re- 
quires extensively purified high molecular mass 
RNA, PCR does not have such stringent re- 
quirements for intact message (indeed, it only re- 
quires that the average molecular mass of template 
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rnRNA be slightly greater than the largest frag- 
ment amplified). Here, we show that using the 
PCR amplification procedure, we can readily 
detect dystrophin transcripts in diagnostic muscle 
biopsy samples. Using both 3 ’ - and 5 ’ -primers, we 
are able to detect these transcripts on either side of 
defined deletions within the dystrophin gene. 
2. EXPERIMENTAL 
2.1. RNA extraction and cDNA synthesis 
Needle muscle biopsies were snap-frozen in isopentane cooled 
in liquid nitrogen and stored at - 70°C or in liquid Nr. Control 
muscle samples were obtained during surgical procedures for 
non-muscle-related isorders. Excess mounting medium was 
removed with a razor blade and total RNA was extracted from 
the frozen muscle using an acid guanidinium thiocyanate (pH 
4.0)/phenol/chloroform method [ll]. cDNA was obtained 
from isolated total RNA (5 pg) using Moloney murine 
leukaemia virus reverse transcriptase (Pharmacia) and either 
reverse or pd(N)6 random primers (Pharmacia). 
2.2. Polymerase chain reaction 
cDNA was amplified with 0.3 fig synthetic dystrophin 
oligonucleotides (final volume 50 pl) (Oligonucleotide Service 
Facility, Royal Postgraduate Medical School) in a program- 
mable temperature bath (Techne) at an annealing temperature 
of 58°C. If the first amplification was negative then the quanti- 
ty of the template was doubled and the process repeated; if this 
second amplification was negative, then G6PD cDNA was co- 
amplified as a control. (The levels of dystrophin mRNA and 
G6PD mRNA are approximately equal in human muscle.) 
Amplified products were separated on l.Wo agarose gels and 
visualized with ethidium bromide. Molecular mass markers 
were obtained from a combined PvuII/TaqI (Boehringer) digest 
of pEMBL DNA (gift from Professor L. Luzzatto, Royal 
Postgraduate Medical School), obtaining fragments of 1443, 
1008, 613, 357, 278, 193 and 103 bp. 
3. RESULTS 
Three pairs of primers derived from the 
dystrophin cDNA sequence were synthesized as 
forward and reverse primers to amplify 3 short 
segments spanning 3 regions of the dystrophin 
coding sequence. Segment I (nucleotides 35-237) is 
situated in the first exon, extending into the un- 
translated region. Segment II (nucleotides 
1854-2070) is situated in exons 14-16 and encom- 
passes part of the cDNA which was originally used 
by Kunkel and colleagues to construct a 90 kDa fu- 
sion protein [4]. Segment III (nucleotides 
9727-9975) is situated 3’ to the so-called ‘hot spot’ 
region which is located between 7 and 8 kb from 
the 5 ‘-end of the molecule (fig.1). The fourth seg- 
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Fig.1. Location of dystrophin PCR primers. Solid line 
represents 14 kb dystrophin cDNA. Filled rectangles indicate 
forward (left) and reverse (right) primers, encompassing PCR- 
amplified segments; I, 204 bp; II, 218 bp; III, 248 bp. (D---; B-- 
-) Deletion in dystrophin cDNA from DMD and BMD patients, 
respectively, referred to in fig.3. The sequences (5’-3’) of the 
primers are: segment I (forward), TCTGGGAGGCAATTAC- 
C’ITC, (reverse) ACAGTCCTCTACTTCTTCCC; segment II 
(forward), ACCGCTGGGTTCTTTTACAA, (reverse) TACA- 
GTTTGCCCATGGATTG; segment III (forward) GCGTGG- 
ATATGTGTCTGAAC, (reverse) CCCCCAAAGGATGCAA- 
CTTCA; segment IV (forward) GTCAAGGTGTTGAAATG, 
(reverse) CTGGCTCCTGCAGAAGAC. 
ment (nucleotides 865-1348) amplified the central 
region of the G6PD cDNA. 
RNA was isolated from small blocks (5-15 mg) 
of muscle biopsy samples taken for diagnostic 
evaluation. The final yield was 1.0-1.5 yg 
RNA/mg tissue. Total RNA was reverse- 
transcribed into single-strand cDNA using either 
pd(N)6 or one of the specific forward primers, 
complementary to the 3 ’ part of the mRNA seg- 
ment to be amplified. Both methods were suc- 
cessful but random primers were finally chosen 
because they gave more reproducible results than 
using a single tube containing a set of specific 
primers. 
The size of the amplification products was as 
predicted from the sequences of dystrophin and 
G6PD cDNA respectively [3,12], namely 
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Fig.2. Agarose gel electrophoresis of amplified dystrophin 
RNA segments from normal muscle biopsies. Lanes: 1, segment 
I; 2, segment II; 3, segment III; 4, coamplification of segment 
I and G6PD (segment IV). 
(dystrophin) segment I, 204 bp; segment II, 
218 bp; segment III, 248 bp; (G6PD) segment IV, 
483 bp. Fig.2 shows these amplification products 
from normal muscle and the co-amplification of 
dystrophin segment I and G6PD segment IV. The 
specificity of the amplified products was establish- 
ed by (i) correct predicted size; (ii) lack of 
amplification when the opposite primers were used 
for cDNA synthesis; (iii) lack of amplification of 
dystrophin segments in human myoblasts. Fig.3 
shows the results of a typical experiment amplify- 
ing total RNA obtained from both DMD and 
BMD muscle. This particular DMD patient was 
deleted for the cDNA probe 44.1 (exons 34-39) 
while the BMD patient had a smaller deletion (ex- 
ons 38-39) which was detected with the same 
probe, both deletions occurring in the central 
(7-8 kb) region of dystrophin cDNA (fig.1). 
Amplified RNA can therefore be detected 3 ’ to the 
identified deletion in both cases. Although 
.3. Agarose gel electrophoresis of amplified dystrophin RNA segments from DMD and BMD muscle. Lanes: 1-3, normal mu! 
segment I; 2, segment II; 3, segment III); 4-6, DMD muscle (4, segment I; 5, segment II; 6, segment III); 7-9, BMD muscle 
segment I; 8, segment II; 9, segment III). 
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transcriptional amplification products are obtain- 
ed for all three regions, there is uneven amplifica- 
tion among the primers; products obtained with 
segment II were distinctly reduced, in both these 
examples and many others. 
4. DISCUSSION 
Dystrophin transcripts in skeletal muscle are 
rare, accounting for O.OOl-0.01% of total RNA. 
Problems in detection are compounded by the in- 
stability of the large message. However, using the 
PCR technique, we can reproducibly detect 
dystrophin message in routine needle muscle biop- 
sies. Samples have been handled without taking 
any specific precautions. We have overcome the 
problems associated with partially degraded RNA 
in stored tissues by only amplifying small segments 
(200-500 bp); PCR does not require intact 
message and it only requires that the molecular 
mass of the template be slightly greater than that 
of the fragment to be amplified. 
The three dystrophin segments were amplified in 
both normal and DMD and BMD muscle. In mus- 
cle from the DMD patient shown here (as well as 
many others; not shown) the dystrophin message 
was detected in the distal region of a genomic dele- 
tion encompassing several exons, indicating that 
transcription was not aborted after the deletion. 
The possibility of using PCR techniques on nee- 
dle muscle biopsies will permit the study of 
dystrophin at the RNA level in virtually all patients 
for which this analysis is of interest. Such informa- 
tion will help in elucidation of many unresolved 
questions: for example, the mechanism of DMD 
gene inactivation in the 35% of patients who do 
not exhibit genomic deletions or duplications in the 
Duchenne gene. It will also be possible to study 
whether non-deletion mutations involve splicing of 
the large dystrophin mRNA [7], or whether some 
of the DMD patients actually have true null muta- 
tions. Finally, it should be feasible to test the 
hypothesis that frameshift deletions in patients 
with a BMD phenotype produce a semi-functional 
protein as a result of reinitiation of the reading 
frame from an internal start codon [ 131. 
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